VHL and pulmonary arterial hypertension: When mice with either VHL or PHD2 mutations develop pulmonary hypertension, it is HIF-2α (via concomitant deletion) that has been shown to be the critical downstream effector (Dai et al., 2018; Hickey et al., 2010; Kapitsinou et al., 2016).